Resveratrol analogue HS-1793 induces the modulation of tumor-derived T cells

YOO JIN CHO1, KWANG MO YANG1, SUNG DAE KIM1, YOUNG HYUN YOO3, SANG WHA LEE2, SU YEONG SEO2, HONGSUK SUH1, SUNG TAE YEE5, MIN HO JEOENG2 and WOL SOON JO1

1Research Center, Dong Nam Institute of Radiological and Medical Sciences, Busan 619-953; Departments of 2Microbiology, and 3Anatomy and Cell Biology, Dong-A University College of Medicine and Mitochondria Hub Regulation Center, Busan 602-714; 4Department of Chemistry and Chemistry Institute for Functional Materials, Pusan National University, Busan 609-735; 5Department of Biology, Sunchon National University, Sunchon, Republic of Korea

Received November 8, 2011; Accepted January 20, 2012

DOI: 10.3892/etm.2012.472

Abstract. Recent advances in the understanding of the mechanisms responsible for tumor progression suggest the possibility to control cancer growth, not only through chemotherapy-induced cancer cell destruction, but also by stimulating anticancer immunity. However, immune tolerance against tumor antigens disturbs diverse forms of immunotherapy. One of the most potent and well-studied tumor-induced immunosuppressive phenotypes found in the tumor microenvironment is the regulatory subpopulation cells (CD4+CD25+FoxP3+ Treg cells). Among the great number of natural agents derived from plants and potentially useful for application in the complementary therapy of cancer, resveratrol is gaining attention for its immunomodulating properties in breast cancer, since the ineffectiveness of numerous immunotherapy strategies may be related, in part, to their negative effects on Treg cells. The present study was undertaken to examine whether HS-1793, a synthetic resveratrol analogue free from the restriction of the metabolic instability and high dose requirement of resveratrol, shows a direct effect on immune responses by enhancing lymphocyte proliferation or an immunomodulatory effect by inducing changes in the Treg cell population in FM3A breast tumor-bearing mice. Although HS-1793 had no direct immunostimulatory effect, it dose-dependently decreased IL-2 secretion and increased IL-4 secretion of concanavalin A-stimulated lymphocytes from tumor-bearing mice, which suggest that HS-1793 may induce changes in the subpopulations of tumor-derived T lymphocytes. The CD4+CD25+ cell population from tumor-bearing mice decreased after HS-1793 treatment in a dose-dependent manner, while the CD4+ T cell population remained unchanged. FoxP3+expressing cells among the CD4+CD25+ population showed a similar pattern. In contrast, the CD8+ T cell population as well as the interferon (IFN)-γ-expressing CD8+ T cell population and IFN-γ secretion of splenocytes from tumor-bearing mice were significantly upregulated by HS-1793 treatment. These results suggest that HS-1793 induces the modulation of tumor-derived T lymphocytes, particularly having a suppressive effect on the Treg cell population, likely contributing to enhanced tumor-specific cytotoxic T lymphocyte responses and CD4+ T cells involving antitumor immunity. Therefore, HS-1793 may serve as a promising adjuvant therapeutic reagent in breast cancer immunotherapy.

Introduction

Cancer cell development and survival is a multifactoral process, involving the genetic mutation of normal cells as well as physiological changes within both cancer cells and the defense mechanisms of the body (1,2). Tumor-infiltrating lymphocytes (TILs) are regarded as a reflection of the tumor-related immune response (3) and are recognized as principal effectors of the local antitumor immune response. However, during the neoplastic process, tumor cells acquire immunotolerance and thereby evade tumor immunity through several specific immune evasion strategies. Tumor-induced immune suppression is caused by numerous mechanisms, many of which involve the accumulation of immune-suppressive infiltrates in the tumor microenvironment (4,5). One of the most potent and well-studied suppressive phenotypes found in the tumor microenvironment is the regulatory subpopulation among CD4+ cells (Treg cells), constitutively expressing high levels of CD25, CTLA-4, GITR and Foxp3, displaying anergy when stimulated by T-cell receptor cross-linking in vitro, and actively inhibiting CD4+CD25+ T cells, CD8+ T cells, dendritic cells, natural killer cells and natural killer T and B cells in a cell to cell contact and dose-dependent
manner (6,7). Increasing evidence shows that Treg cells play an important role in immune evasion mechanisms employed by cancer (8-10). Tumors may differentiate, expand, recruit and activate Treg (tumor Treg) cells via multiple mechanisms and potently abrogate antitumor immunity (11). These recent advances in the understanding of the mechanisms responsible for tumor progression suggest the possibility to control cancer growth, not only through chemotherapy-induced cancer cell destruction, but also by stimulating anticancer immunity. Diverse forms of immunizations have been suggested to have the potential to completely eradicate cancer (12).

In addition to the existence of endogenous antitumor molecules, several agents capable of stimulating the anticancer immunity have also been isolated from plants. Among the great number of natural agents derived from plants which are potentially useful for application in the complementary therapy of cancer, resveratrol has gained attention since it has been shown to inhibit cellular events associated with tumor initiation, promotion and progression in various types of solid tumors (13,14) and to enhance immune responses in mice by promoting production of Th1 cytokines, such as interleukin (IL)-12 and interferon (IFN)-γ, and by enhancing lymphocyte proliferation and IL-2 production (15). In the case of breast cancer, resveratrol has also been reported to inhibit the in vitro growth of a number of human and mouse breast cancer cell lines which are both estrogen receptor (ER)-positive and ER-negative (16). Yet, exposure to high doses of resveratrol is required to induce chemopreventive and chemotherapeutic properties against the tumor itself, and the biological activity of resveratrol is limited by its photosensitivity and metabolic instability.

Our previous study was undertaken to design and synthesize analogues of resveratrol with potent activity (17) and we demonstrated that four synthetic resveratrol analogues (HS-1784, -1792, -1791 and -1793) displayed stronger anti-tumor effects than resveratrol in most cancer cells tested, including the MCF-7 human breast adenocarcinoma cell line (18). A resveratrol analogue, 4-(6-hydroxy-2-naphthyl)-1,3-benzenediol (HS-1793), particularly overcomes the resistance conferred by Bcl-2 by inducing apoptosis. However, considerable uncertainty remains in regards to the effect of HS-1793 on tumor immunity. Meanwhile, it was reported that immunomodulatory and anticancer properties can conceivably be controlled by the suppression of the Treg cell population, which makes the peritumoral microenvironment unfavorable to the tumor and eventually results in growth inhibition of tumor cells (19). The present study was undertaken to examine whether HS-1793 exhibits a direct effect on immune responses by enhancing lymphocyte proliferation or an immunomodulating effect by inducing changes in the Treg cell population in tumor-bearing mice.

Materials and methods

Preparation of the resveratrol analogue HS-1793. To obtain HS-1793, the stilbene double bond present in resveratrol was substituted with a naphthalene ring as previously described (17,18). A stock solution of HS-1793 was made in absolute ethanol at 10 mM and stored at -20°C. Working dilutions (0.3, 0.6, 1.3 and 2.5 µM), at which no toxic effect had been observed, were directly made in the tissue culture medium. The control vehicle used was the tissue culture medium containing amounts of ethanol equivalent to those present in HS-1793.

Animals and cells. All experiments were carried out on 6-week-old female C3H/He mice obtained from Central Lab. Animal, Inc. (Seoul, Korea). The colony was maintained under controlled conditions of temperature (19-25°C), humidity (40-60%) and a 12-h light-dark cycle with the light intensity of 150-300 Lux. The animals were housed in sanitized polycarbonate cages (200 width x 260 length x 130 height). They had free access to standard mouse food and water. All animals were raised under SPF condition at the Korea Institute of Toxicology, Hospital of Dong-A University according to the Good Laboratory Practices (GLP) OECD guidelines. All animal procedures were performed according to approved protocols (approval no. DIACUC-09-24) from the Institutional Animal Care and Use Committee (IACUC) of Dong-A University, and in accordance with recommendations for the proper use and care of laboratory animals. FM3A murine breast cancer cells originating from the mammary gland of the C3H/He mouse and cells were cultured in RPMI-1640 medium (Invitrogen, Carlsbad, CA, USA) supplemented with 2 mM L-glutamine, 100 U/ml penicillin, 100 µg/ml streptomycin and 10% heat-inactivated fetal bovine serum (FBS; Invitrogen) at 37°C in a humidified, 5% CO₂ atmosphere. Cells were used for experiments in the log phase of growth. For the preparation of tumor-bearing mice, FM3A cells in logarithmic growth phase (2x10⁵ cells/50 µl saline) were inoculated subcutaneously in the right flank of female C3H/He mice. When the tumor grew to a size of ~10 mm in diameter (~4 weeks), the spleen was aseptically removed. A single-cell suspension was prepared by gently teasing the cells through a sterile stainless steel screen and the erythrocytes were lysed at room temperature using ACK lysis buffer (NH₄Cl, KHCO₃, and Na₂EDTA). The isolated splenocytes were suspended in complete medium (RPMI-1640 supplemented with 10% FBS, 50 µM 2-mercaptoethanol, 100 U/ml penicillin and 100 µg/ml streptomycin) and cultured at 37°C in a humidified, 5% CO₂ atmosphere.

Lymphocyte proliferation assay. Lymphocyte proliferation was determined by BrdU (5-bromo-2-deoxyuridine) incorporation assay using a cell suspension at 5x10⁵ cells/well in flat-bottom 96-well microculture plates. The cells were cultured for 48 h and further incubated for 24 h in the presence of 10 µl of the BrdU solution in RPMI medium (1:100 diluent). The BrdU incorporation was measured using the Cell Proliferation ELISA BrdU kit (Roche Diagnostics-Applied Science, Mannheim, German), following the supplier's specifications.

Lymphocyte subpopulation analysis. Lymphocyte subpopulations were determined by flow cytometric analysis. The freshly prepared splenocytes were washed three times with ice cold PBS-containing 0.1% FBS and then stained with appropriately diluted labeled anti-mouse antibodies [anti-CD4 FITC (BD Biosciences Pharmingen), anti-CD8 PE (BD Biosciences Pharmingen), anti-CD25 PERCP-Cy5.5 (eBioscience) and isotypic controls (BD Biosciences)] at 0.1-0.5 µg/ml for 40 min on ice. For the identification of intracellular IFN-γ expression in CD8⁺ T cells, the freshly prepared cells were stimulated...
with PMA (50 ng/ml; Sigma) and ionomycin (500 ng/ml; Sigma) for 2 h and further incubated with protein transport inhibitor brefeldin A (10 µg/ml; Sigma) for 2 h to accumulate for intracellular cytokines. At the end of the incubation, Fc Block (BD Biosciences Pharmingen) was added for 15 min at 4°C, and standard surface staining procedures were performed with anti-CD8 PE. The cells were then fixed, permeabilized and stained with anti-IFN-γ FITC (BD Biosciences Pharmingen). Following staining, cells were washed and analyzed immediately using the FC500 flow cytometer (BD FACSAria, USA). Two-color flow cytometric analyses were performed, and data represent 50,000 events, unless otherwise noted. The phenotype of Treg cells (CD4+CD25+FoxP3+) was evaluated by three-color fluorescence flow cytometric analysis following standard surface staining procedures combined with intracellular FoxP3 staining method. Intracellular detection of FoxP3 was performed using PE anti-mouse FoxP3 staining buffer set purchased from eBioscience. Briefly, the cells stained with anti-CD4-FITC and anti-CD25-PERCP-Cy5.5 were washed, fixed and permeabilized according to the manufacturer's instructions, and then incubated with PE-conjugated rat anti-mouse FoxP3 Ab for 40 min on ice.

Cytokine production assay. The splenocytes from the mice were cultured for 24 h at 10^7 cells/ml in serum-free RPMI medium containing 200 µg/ml BSA. IL-2, IL-4 and IFN-γ concentrations were determined in the supernatant using enzyme-linked immunosorbent assay kits (ELISA; BD Biosciences Pharmingen) according to the manufacturer's instructions.

Statistical analysis. All statistical analyses were performed using commercially available statistical software (SPSS Inc., Chicago, IL, USA). Results are expressed as the means ± standard deviation (SD), and numerical data were analyzed by the Student's t-test or one-way analysis of variance (ANOVA). For all analyses, a difference was considered to be significant at a P-value of <0.05.

Results

**HS-1793 induces immunomodulation in tumor-bearing mice.** To examine whether HS-1793 gives rise to direct immunostimulating activity, the lymphocyte proliferative response was tested by BrdU incorporation assay. HS-1793 at doses of 0.3-2.5 µM did not induce lymphocyte proliferation in normal as well as tumor-bearing mice. The concanavalin A (ConA)-stimulated lymphocyte proliferative response of splenocytes from tumor-bearing mice, which was lower than that of normal mice, was also unaltered by the treatment of HS-1793 (Fig. 1A).

Having confirmed the presence of cytokines for the development of effector T cells and Treg cells, the cultured supernatants of ConA-stimulated lymphocytes were analyzed for the production of IL-2 and IL-4. Tumor-bearing mice showed a decrease in IL-2 production after HS-1793 treatment in a dose-dependent manner and an increase in IL-4 production (Fig. 1B and C), which indicates that HS-1793 may induce changes in the subpopulations of tumor-derived T lymphocytes. Thus, immunofluorescent analysis for cell surface markers using flow cytometric analysis was performed to investigate T lymphocyte subpopulations. The average frequency of CD4+ T cells among total splenocytes from the
tumor-bearing mice was generally lower compared to that in the normal mice and was not significantly changed by HS-1793 treatment (Fig. 2A). CD8\(^+\) T cells exhibited a similar profile of frequency when comparing the tumor-bearing mice to normal mice; however, HS-1793 treatment prominently recovered the frequency of CD8\(^+\) T cells in tumor-bearing mice (Fig. 3A). These results suggest that HS-1793 does not induce direct immunostimulation, but has immunomodulating activity on tumor-derived T lymphocytes.

**HS-1793 suppresses Treg cells in tumor-bearing mice.** To investigate the effect of HS-1793 on the Treg cell population, CD4\(^+\)CD25\(^+\) cell proportions were determined by flow cytometric analysis after HS-1793 treatment in splenocytes from normal and tumor-bearing mice. Based on the changes in the average frequency of CD4\(^+\) T cells, comparison of the CD4\(^+\)CD25\(^+\) to CD4\(^+\) cell ratio was better for discriminating the differences between groups. The ratio of CD4\(^+\)CD25\(^+\) to CD4\(^+\) cells was not changed in the normal mice; however, a significant decrease was noted in the tumor-bearing mice in a dose-dependent manner (Fig. 2B). The expression of FoxP3, a specific Treg cell marker, was further investigated to confirm that the CD4\(^+\)CD25\(^+\) cells reduced by HS-1793 are true Treg cells. The proportion of the FoxP3\(^+\) cells among CD4\(^+\)CD25\(^+\)
cells in the FM3A tumor-bearing mice, which was higher than that from the normal mice, showed a similar, but more prominent pattern of decrease (Table I). In contrast, the FoxP3<sup>+</sup> cells among the CD4<sup>+</sup>CD25<sup>+</sup> cells were almost unchanged at a minimal level. These results showed that HS-1793 effectively suppressed the Treg cell population without affecting CD4<sup>+</sup> cells in the tumor-bearing mice.

**HS-1793 enhances IFN-γ-expressing CD8<sup>+</sup> T cells in tumor-bearing mice.** We finally investigated whether HS-1793 enhances effector T cells involved in antitumor immunity in tumor-bearing mice. The number and percentage of IFN-γ-expressing CD8<sup>+</sup> T cells in tumor-bearing mice were significantly increased in a dose-dependent manner after HS-1793 treatment, compared to the values in normal mice (Fig. 3B). In addition, IFN-γ secreted in the cultured supernatants of splenocytes from tumor-bearing mice also showed an increase after HS-1793 treatment in a dose-dependent manner, which indicates an unfavorable change in the tumor microenvironmental and the induction of effective antitumor immunity (Fig. 3C).

**Discussion**

In recent years, there has been considerable interest in resveratrol as a potential cancer chemotherapeutic and immunomodulating agent. However, resveratrol is not a potent cytotoxic compound when compared to other chemotherapeutic drugs, and its stilbene double bonds are readily oxidized. Resveratrol analogue HS-1793 containing a different position of two of three hydroxyl groups at the aromatic ring without the unstable double bond, was, on the other hand, described to display stronger antitumor effect than resveratrol in most cancer cells, to overcome the resistance conferred by Bcl-2 in U937 cells via 14-3-3, and to exert its antitumor activity via Bad (18). The results presented in this study clarified the modulating effect of HS-1793 on tumor-derived T lymphocytes, which implies that HS-1793, having both immunomodulatory and antitumor effects, may be an appropriate candidate agent for production of an ideal conditioning strategy against pre-established cancer.

**Table I. Expression of FoxP3 on gated CD4<sup>+</sup>CD25<sup>+</sup> or CD4<sup>+</sup>CD25<sup>+</sup> cells in tumor-bearing mice after HS-1793 treatment.**

<table>
<thead>
<tr>
<th>Test group</th>
<th>Concentration of HS-1793 (µM)</th>
<th>FoxP3-expressing cells/CD4&lt;sup&gt;+&lt;/sup&gt;CD25&lt;sup&gt;+&lt;/sup&gt; cells</th>
<th>FoxP3-expressing cells/CD4&lt;sup&gt;+&lt;/sup&gt;CD25&lt;sup&gt;+&lt;/sup&gt; cells</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Events no.</td>
<td>% Gated</td>
<td>Events no.</td>
</tr>
<tr>
<td>Normal mice</td>
<td>-</td>
<td>125/684</td>
<td>18.2±4.8</td>
</tr>
<tr>
<td>Tumor bearing mice</td>
<td>0.0</td>
<td>502/745</td>
<td>67.6±9.4&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td></td>
<td>0.3</td>
<td>328/584</td>
<td>56.3±5.0</td>
</tr>
<tr>
<td></td>
<td>0.6</td>
<td>213/450</td>
<td>48.2±15.3</td>
</tr>
<tr>
<td></td>
<td>1.3</td>
<td>125/346</td>
<td>36.7±10.2&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
<tr>
<td></td>
<td>2.5</td>
<td>56/195</td>
<td>28.7±6.8&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
</tbody>
</table>

FoxP3 expression in the spleen of tumor-bearing mice (n=5) was determined by intracellular FACS analysis. Results are expressed as the percentage of FoxP3-expressing cells within CD4<sup>+</sup>CD25<sup>+</sup> cells or CD4<sup>+</sup>CD25<sup>+</sup> cells. Data are reported as the means ± SD of 5 mice per group. <sup>a</sup>P<0.05 as compared to normal mice; <sup>b</sup>P<0.05 as compared to untreated control. The significance of differences among the treated groups was evaluated by the Student’s t-test or Dunnett’s test.

We investigated the direct immunostimulating effect of HS-1793, which had no effect on lymphocyte proliferation at doses of 0.3-2.5 µM. However, it is noteworthy that IL-2 and IL-4 secretion of ConA-stimulated lymphocytes from tumor-bearing mice was modulated in a dose-dependent manner by HS-1793 at these doses (Fig. 1). The result suggests that HS-1793 induces changes in the subpopulations of tumor-derived T lymphocytes. The average frequency of the CD4<sup>+</sup> T cell population among total splenocytes from tumor-bearing mice, which was lower than that from normal mice, was not significantly changed by HS-1793 treatment. However, the CD4<sup>+</sup>CD25<sup>+</sup> cell population from the tumor-bearing mice, which was higher than that in the normal mice, exhibited a HS-1793-dose-dependent decrease, and this decreasing trend in the CD4<sup>+</sup>CD25<sup>+</sup> cell population became more definite when it was illustrated in terms of the CD4<sup>+</sup>CD25<sup>+</sup> to CD4<sup>+</sup> cell ratio (Fig. 2). The regulatory subpopulation among CD4<sup>+</sup> cells constitutively expressing high levels of CD25 (Treg cells) is one of the most potent and well-studied suppressive phenotypes found in the tumor microenvironment.

It may be assumed that HS-1793 inhibited the IL-2 secretion and promoted the IL-4 secretion of tumor-derived T lymphocytes, which downregulated CD25<sup>+</sup>-expressing CD4<sup>+</sup> T cells more sensitively. Actually, IL-2 and IL-4 are essential for naturally occurring Treg cell homeostasis and activation. Treg cells are refractory to TCR-induced proliferation (20,21) and depend on IL-2 for survival (22,23). The signaling via the high-affinity IL-2R complex, in combination with TCR engagement, is essential for Treg cell proliferation as well as the acquisition of their potent suppressive function (23). Stimulation of Treg cells with IL-2 leads to phosphorylation and activation of STAT5 and consequently, binding to the forhead box P3 (FoxP3) promoter, resulting in enhanced FoxP3 expression (24). By contrast, IL-4 inhibited TGF-β-induced Foxp3 expression and thus suppressed the new generation of Foxp3<sup>+</sup> Treg cells (25). The transcriptional factor FoxP3 is a crucial developmental and functional factor expressed in Treg cells (20), and is regarded as a useful intracellular Treg cell marker. Thus, we investigated the expression of FoxP3 to more clearly define Treg cells. FoxP3 was expressed mainly in the CD4<sup>+</sup>CD25<sup>+</sup>...
cell population and was extensively increased in cells from tumor-bearing mice. Moreover, the CD4\(^+\)CD25\(^+\)FoxP3\(^+\) to CD4\(^+\)CD25\(^-\) cell ratio decreased significantly after treatment with HS-1793 in a dose-dependent manner (Table I).

It is generally recognized that IFN-\(\gamma\)-producing CD8\(^+\) T cells play an important role in inhibiting and killing tumor cells and impeding tumor growth, which requires effector CD4\(^+\) help (26) and can be largely affected by the presence of regulatory CD4\(^+\) cells (27). Regulatory CD4\(^+\) cells promote CD8\(^+\) T cell ablation by preventing licensing of APCs by Th1 effector cells, or educating tolerogenic APCs (28), or directly modulating CD8\(^+\) T cells (29). As shown in the results of our present study, the average frequency of the CD8\(^+\) T cell population among total splenocytes from the tumor-bearing mice, which was lower than that from normal mice, was significantly increased by HS-1793 treatment. The IFN-\(\gamma\)-producing CD8\(^+\) T cell population as well as IFN-\(\gamma\) secretion of splenocytes from tumor-bearing mice also showed a HS-1793-dose-dependent increase (Fig. 3). IFN-\(\gamma\) plays a key role in Th helper 1 cell responses and tumor surveillance and immunoeediting, and appears to be one of the most significant cytokines preventing and suppressing the development of cancers. In parallel, IFN-\(\gamma\) blocks TGF-\(\beta\)-mediated Treg cell differentiation (30). Although the exact mechanism of enhanced IFN-\(\gamma\) expression in CD8\(^+\) cells by HS-1793 is not clear, it may be related in part to HS-1793-induced Treg cell depletion in tumor-bearing mice.

Based on the results of our present and previous studies, HS-1793 itself could be applied as an adequate principal therapeutic agent, facilitating the immune system against pre-established cancer and inducing apoptosis of cancer cells. However, HS-1793 may be more effective clinically when it is used in combination with other main cancer therapies, such as chemotherapy agents, ionizing radiation or tumor vaccines, since one of the major obstacles that must be overcome to achieve successful cancer treatment is tumor-induced immune suppression caused by Treg cells. Actually, the presence of Treg cells is demonstrated in the tumor microenvironment; higher numbers of Treg cells are associated with progression in a variety of malignancies, including a variety of solid tumors as well as haematological malignancies. In addition, increased populations of Treg appear to correlate with poor survival in several types of cancers. Therefore, effective Treg cell elimination is critical for both primary treatment and secondary prevention (i.e., relapse or recurrence) of cancer. Indeed, our previous study demonstrated that Treg cell depletion, treated by a low dose of cyclophosphamide, potentiated the antitumor effect of immunization with an injection of immature dendritic cells into irradiated tumors (31). As well as in breast cancer, Treg cells were increased in the peripheral blood and greatly increased in the tumor microenvironment (32); the presence of Treg cells is likely to correlate with cancer progression (33), and specific depletion of Treg cells markedly inhibits tumor growth and maintains a strong and persistent antitumor immune response (34).

The present study revealed that HS-1793 effectively suppressed the Treg cell population and enhanced IFN-\(\gamma\) production of CD8\(^+\) T cells in FM3A breast cancer cell-bearing C3H/He mice. Furthermore, another advantage of HS-1793 involves the fact that the CD4\(^+\) cell pool did not decrease, which may include tumor-specific CD4\(^+\) cells involved in antitumor immunity. In light of this, HS-1793, free from the restriction of metabolic instability and high-dose requirement of resveratrol, is a promising candidate agent for adjuvant therapy in breast cancer immunotherapy, and is able to confer a bystander effect in eradicating chemotherapy or radiotherapy-resistant cancer cells and synergistically act when treated with dendritic cell vaccine.

Acknowledgements

This study was supported by the Nuclear R&D Program through the Dong Nam Institute of Radiological and Medical Sciences funded (code 50593-2011) by the Ministry of Education, Science and Technology, and by a grant of the Korea Healthcare Technology R&D Project, Ministry of Health and Welfare, Republic of Korea (A090314).

References